Raymond James Financial Inc. Buys Shares of 119,261 Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Raymond James Financial Inc. bought a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 119,261 shares of the company’s stock, valued at approximately $5,494,000.

Several other large investors have also recently bought and sold shares of the company. R Squared Ltd bought a new position in shares of Establishment Labs during the fourth quarter worth $36,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Establishment Labs during the third quarter worth about $127,000. Handelsbanken Fonder AB grew its stake in Establishment Labs by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company’s stock valued at $378,000 after acquiring an additional 2,000 shares during the period. Verition Fund Management LLC increased its holdings in shares of Establishment Labs by 22.8% in the third quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock worth $407,000 after acquiring an additional 1,746 shares in the last quarter. Finally, Maven Securities LTD acquired a new stake in shares of Establishment Labs during the third quarter worth about $433,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Up 3.9 %

NASDAQ:ESTA opened at $41.22 on Tuesday. The stock has a 50-day simple moving average of $35.85 and a 200 day simple moving average of $40.85. Establishment Labs Holdings Inc. has a 52-week low of $28.16 and a 52-week high of $60.12. The company has a market cap of $1.19 billion, a PE ratio of -15.98 and a beta of 0.95. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm had revenue of $44.51 million for the quarter, compared to analyst estimates of $44.45 million. On average, sell-side analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “overweight” rating and issued a $52.00 price objective on shares of Establishment Labs in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.40.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.